Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors.

Authors:
Mukherjee D; Topol EJ.

Journal:
Arthritis Res Ther

Publication Year: 2002

DOI:
10.1186/ar609

PMCID:
PMC154429

PMID:
12716442

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Arthritis Res Ther

Abbreviation: Arthritis Res Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Rheumatology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
ADAM8 silencing suppresses the migration and invasion of fibroblast-like synoviocytes via FSCN1/MAP…
Chen K; Tao H; Zhu P and 9 more (2024) - Transparency Score: 3/6
Apolipoproteins and the risk of giant cell arteritis-a nested case-control study.
Wadström K; Jacobsson LTH; Mohammad AJ and 3 more (2024) - Transparency Score: 3/6
A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration duri…
Nakai T; Honda N; Soga E and 4 more (2024) - Transparency Score: 4/6
Autoimmune congenital heart block: a case report and review of the literature related to pathogenes…
Huang Y; Deng J; Liu J and 2 more (2024) - Transparency Score: 3/6
B cell receptor repertoire analysis in primary Sjogren's syndrome salivary glands identifies repert…
Chang L; Zheng Z; Zhou Y and 11 more (2024) - Transparency Score: 5/6
View All Papers from This Journal
Transparency Score
0/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025